FilingSEC EDGAR8-K
Citius Pharmaceuticals Receives Nasdaq Bid Price Rule Compliance Extension Until February 8, 2027
· SEC accepted
StageExtension granted
Filing content
The company received a Nasdaq extension until February 8, 2027, to regain compliance with the minimum bid price requirement.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…